HD patients with GT2 HCV infection
Conditions
Interventions
None listed
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Hemodialysis patients with genotype 2 HCV infecton, who initiated on glecaprevir/pibrentasvir
Exclusion criteria
Exclusion criteria: 1 Patients with a past history of hypersensitivity to HCV protease inhibitors and NS5A inhibitors 2 Patients with serious liver dysfunction (Child-Pugh Class B or C) 3 Patients with difficult-to-control heart disease (e.g., myocardial infarction, heart failure, and arrhythmia) 4 Patients who have malignant tumors, including hepatoma, at the start of treatment 5 Patients on treatment with drugs listed in the contraindications for coadministration in the package insert (e.g., some antifungals, some antiepileptics, and human immunodeficiency virus (HIV) protease inhibitors) 6 Other patients judged to be inappropriate to participate in the study by the primary physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sustained virological response adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 efficacy and safety in patients with or without LC 2 association of RAVs and SVR 3 efficacy and safety in patients who previously failed to DAAs 4 RAVs in patients failed to GP therapy 5 improvement of liver function after SVR. 6 improvement of AFP value 7 changes in lipid and glucose metabolism 8 adverse events 9 SVR rate according toage | — |
Countries
Japan
Contacts
Public ContactGoki Suda
Graduate School of Medicine,Hokkaido University Department of Gastroenterology and Hepatology
Outcome results
None listed